FIRST aMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • November 8th, 2019 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Maryland
This FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 10th day of September, 2019, by and among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation (“BioCryst”), MDCP, LLC, a Delaware limited liability company (“Peramivir SPE”, and together with BioCryst, collectively in the singular, “Borrower”), MIDCAP FINANCIAL TRUST, as Agent for Lenders (in such capacity and together with its permitted successors and assigns, the “Agent”) and the other financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
Second aMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • November 8th, 2019 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Maryland
This SECOND AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 13th day of September, 2019, by and among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation (“BioCryst”), MDCP, LLC, a Delaware limited liability company (“Peramivir SPE”, and together with BioCryst, collectively in the singular, “Borrower”), MIDCAP FINANCIAL TRUST, as Agent for Lenders (in such capacity and together with its permitted successors and assigns, the “Agent”) and the other financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
